Predicting oligonucleotide therapeutic efficacy at the population level

Area of Science:

• Molecular Biology
• Pharmacogenomics
• Genetics

Background:

• DNA-directed RNA interfering (RNAi) mediators are generally insensitive to single nucleotide polymorphisms (SNPs).
• Current methods for validating oligonucleotide drug efficacy against SNPs are limited to experimental evaluation of a few known SNPs in a population.
• This limits the comprehensive assessment of drug effectiveness across diverse genetic profiles.

Purpose of the Study:

• To develop a novel method for assessing the relative sensitivity of all known and unknown polymorphisms to oligonucleotide-based therapeutics.
• To overcome the sampling limitations inherent in current SNP validation approaches.
• To enable unbiased, population-level pharmacodynamic studies for sequence-specific oligonucleotide drugs and genome editing tools.

Main Methods:

• Utilized ultra-deep next-generation sequencing (NGS) to analyze drug effects in vitro.
• Developed a method to test drug efficacy against all possible SNPs of a molecular target in a patient-free manner.
• Presented technical details of the approach for comprehensive polymorphism sensitivity reporting.

Main Results:

• The developed method allows for the comprehensive evaluation of drug sensitivity across all potential SNPs of a molecular target.
• Enables in vitro testing of drug effects on all possible SNPs, overcoming previous experimental constraints.
• Provides a patient-free approach for assessing drug impact on diverse genetic variations.

Conclusions:

• The new NGS-based method facilitates unbiased pharmacodynamic studies at the population level for oligonucleotide drugs.
• This approach significantly enhances the ability to predict drug efficacy across a wide range of genetic polymorphisms.
• Empowers the development and application of sequence-specific oligonucleotide therapeutics and genome editing tools by providing a more complete understanding of SNP interactions.